HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Charles H Graham Selected Research

Nitroglycerin (Dynamite)

2/2014A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
1/2014Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia.
5/2012Nitroglycerin prevents coagulopathies and foetal death associated with abnormal maternal inflammation in rats.
12/2011Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide.
6/2011Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissues.
10/2009Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
6/2008Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide.
4/2007Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.
3/2007Glyceryl trinitrate inhibits hypoxia/reoxygenation-induced apoptosis in the syncytiotrophoblast of the human placenta: therapeutic implications for preeclampsia.
1/2004Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Charles H Graham Research Topics

Disease

20Anoxia (Hypoxia)
12/2014 - 06/2002
17Neoplasms (Cancer)
02/2014 - 02/2002
7Carcinoma (Carcinomatosis)
11/2010 - 09/2002
4Pre-Eclampsia (Preeclampsia)
06/2011 - 09/2006
4Prostatic Neoplasms (Prostate Cancer)
10/2009 - 09/2003
4Neoplasm Metastasis (Metastasis)
06/2007 - 09/2002
3Inflammation
01/2014 - 03/2012
3Necrosis
05/2012 - 09/2006
2Disseminated Intravascular Coagulation
05/2012 - 03/2012
2Thrombophilia
05/2012 - 03/2012
2Breast Neoplasms (Breast Cancer)
01/2012 - 03/2007
2Adenocarcinoma
06/2009 - 09/2003
2Pathologic Processes
03/2005 - 02/2002
1Pregnancy Complications
01/2014
1Reperfusion Injury
09/2006
1Melanoma (Melanoma, Malignant)
01/2004

Drug/Important Bio-Agent (IBA)

13Nitric Oxide (Nitrogen Monoxide)FDA Link
02/2014 - 09/2002
12Nitroglycerin (Dynamite)FDA LinkGeneric
02/2014 - 09/2002
6Doxorubicin (Adriamycin)FDA LinkGeneric
04/2013 - 09/2003
4Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
06/2007 - 09/2002
3MelatoninIBA
01/2012 - 10/2009
3Etoposide (VP 16)FDA LinkGeneric
11/2010 - 07/2008
3Carbon MonoxideIBA
09/2006 - 09/2003
3OxygenIBA
03/2005 - 02/2002
2Transcription Factors (Transcription Factor)IBA
02/2014 - 01/2008
2micaIBA
04/2013 - 12/2011
2TNFR-Fc fusion protein (etanercept)FDA Link
05/2012 - 03/2012
2Dacarbazine (DIC)FDA LinkGeneric
05/2012 - 03/2012
2Messenger RNA (mRNA)IBA
06/2011 - 06/2002
2Small Interfering RNA (siRNA)IBA
06/2009 - 07/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2007 - 02/2003
28-bromocyclic GMPIBA
04/2007 - 09/2002
15'-Guanylic Acid (GMP)IBA
12/2014
1Anti-Inflammatory Agents (Anti-Inflammatories)IBA
01/2014
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2014
1antineoplaston A10 (A 10)IBA
01/2014
1FibrinIBA
03/2012
1Biological Markers (Surrogate Marker)IBA
01/2012
1HormonesIBA
01/2012
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
06/2011
1Tyrosine (L-Tyrosine)FDA Link
06/2011
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
11/2010
1Fluorouracil (Carac)FDA LinkGeneric
11/2010
12- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
11/2010
1Vincristine (Oncovin)FDA LinkGeneric
11/2010
1Prostate-Specific Antigen (Semenogelase)IBA
10/2009
1DNA (Deoxyribonucleic Acid)IBA
06/2009
1Hypoxia-Inducible Factor 1IBA
06/2009
1Mitoxantrone (Novantrone)FDA LinkGeneric
07/2008
1AnthracyclinesIBA
07/2008
1AnthraquinonesIBA
07/2008
1Daunorubicin (Cerubidine)FDA LinkGeneric
07/2008
1NK Cell Lectin-Like Receptor Subfamily KIBA
06/2008
1InterleukinsIBA
06/2008
1Glutathione (Reduced Glutathione)IBA
01/2008
1NF-kappa B (NF-kB)IBA
01/2008
1DNA Repair EnzymesIBA
01/2008
1IntegrinsIBA
06/2007
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
06/2007
1Urokinase Plasminogen Activator ReceptorsIBA
06/2007
1Cadherins (E-Cadherin)IBA
06/2007
1Paclitaxel (Taxol)FDA LinkGeneric
04/2007
1Isosorbide Dinitrate (Isordil)FDA LinkGeneric
04/2007
1pimonidazoleIBA
03/2007
1Deoxycytidine (CDR)IBA
03/2007
1LuciferasesIBA
03/2007
1Ribose (D-Ribose)IBA
03/2007
1Interleukin-10 (Interleukin 10)IBA
03/2007
1Peptide Receptors (Peptide Receptor)IBA
02/2007
1Natriuretic PeptidesIBA
02/2007
1FibrinolysinFDA Link
06/2006
1Glucose (Dextrose)FDA LinkGeneric
06/2006
1Plasminogen Activators (Plasminogen Activator)IBA
06/2006
1Blood Glucose (Blood Sugar)IBA
06/2006
11- hydroxy- 2- oxo- 3,3- bis(2- aminoethyl)- 1- triazeneIBA
01/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
02/2003
1matrigelIBA
02/2003
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
02/2003
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
02/2003
1Deferoxamine (Desferal)FDA LinkGeneric
09/2002

Therapy/Procedure

3Drug Therapy (Chemotherapy)
04/2007 - 09/2003
2Immunotherapy
02/2014 - 06/2008
2Cutaneous Administration
02/2014 - 01/2014
2Heterologous Transplantation (Xenotransplantation)
04/2013 - 04/2007
1Castration
01/2014
1Radiotherapy
10/2009